Agios Pharmaceuticals vs Eton Pharmaceuticals
AGIO and ETON side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGIO and ETON compare
Agios Pharmaceuticals and Eton Pharmaceuticals are about the same size, with market caps of $1.9B and $1.8B.
Agios Pharmaceuticals grew revenue faster over the last twelve months (214% versus 101% for Eton Pharmaceuticals).
Eton Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.3% compared with −265% at Agios Pharmaceuticals.
Agios Pharmaceuticals scores higher on the StockData Score (13 against 12 for Eton Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGIO | ETON |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $1.8B |
| Share price | $31.59 | $63.93 |
| Change, 1 year | −27.6% | 266% |
| Change, 5 years | −17.3% | 1302% |
| Beta (5Y) | 1.41 | 0.88 |
| Employees | 539 | 44 |
| StockData Score | ||
| Total score | 13 (better) | 12 |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 42.1× |
| P/S | 13.4× | 13.0× (better) |
| P/B | 1.9× (better) | 21.0× |
| EV/EBITDA | – | 39.3× |
| P/FCF | – | 47.8× |
| FCF yield | −17.8% | 2.1% (better) |
| Fair value | $32.10 | $33.76 |
| Margin of safety | 1.6% (better) | −89.4% |
| Growth | ||
| Revenue growth (TTM) | 214% (better) | 101% |
| Revenue growth, 5Y average | – | 360% |
| Profitability | ||
| Gross margin | 93.8% (better) | 69.2% |
| Operating margin | −298% | 28.8% (better) |
| Net margin | −265% | 35.3% (better) |
| FCF margin | −239% | 27.1% (better) |
| Return on equity | −32.9% | 90.6% (better) |
| Return on invested capital | −1169% | 115% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.27 (better) |
| Net debt / EBITDA | – | −0.71 |
| Current ratio | 9.69 (better) | 1.79 |
| Altman Z-score | 11.86 | 17.09 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 111% | 74.0% |
| Held by insiders | 1.1% | 5.6% |
| Insider net buying, 12 months | −$4.9M (better) | −$35.0M |
| Short interest, % of float | 11.1% | 7.4% |
Go deeper
- AGIO stock overview
- AGIO income statement
- AGIO valuation and score
- ETON stock overview
- ETON income statement
- ETON valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.